BMJ Nutrition, Prevention & Health

Prevalence of non-communicable diseases by age, gender and nationality in publicly funded primary care settings in Qatar

Mohamed A Syed 💿 , Ahmed S Alnuaimi, Abdul Jaleel Zainel, Hamda A A/Qotba

ABSTRACT Background In Qatar, as with other countries, non-

strategies.

communicable diseases (NCDs) have been the leading

cause of death. This study aims to describe the prevalence

of four NCDs clusters (cardiovascular diseases (coronary

heart disease, stroke and peripheral vascular disease),

(Qataris and non-Qataris) accessing publicly funded

cancers, chronic obstructive pulmonary diseases (COPD)

primary care services to inform healthcare planning and

Methods Cross-sectional study design was used. Data

Results The findings showed that approximately 16.2

% of the study population (N = 68421) had one or more

increasing trend with increasing age. Highest increases

in the prevalence of NCDs were seen in a relatively young

of the four NCDs. The prevalence of NCDs showed an

age group (30–49 years). The prevalence of all NCDs except cancers was higher in men. Prevalence rates of

CHD and cancers in the study were found to be similar

T2DM rates were higher in Qataris compared with non-

Qataris. T2DM accounted for the highest prevalence of

any NCD among both Qataris (230/1000) and non-Qataris

Conclusions Although not comprehensive and nationally

Western European nationalities. Prevention, treatment and

control of NCDs and their risk factors are a public health

prevalence of NCDs among a younger population, men and in Qatari, Western Asian, Southern Asian, Sub-Saharan

Africans, South-Eastern Asians Northern African and

problem in Qatar, and resources need to be invested

towards targeted interventions with a multisectoral

representative, this study is suggestive of a higher

in both Qataris and non-Qataris; however, COPD and

from electronic medical records and analysed.

for individuals aged ≥18 and who visited a publicly funded

primary health centre in Qatar during 2017 were extracted

and type 2 diabetes (T2DM)) by age, gender and nationality

published online only. To view please visit the journal online (http://dx.doi.org/10.1136/ bmjnph-2018-000014).

Additional material is

Directorate of Clinical Affairs, Department of Clinical Research, Primary Health Care Corporation, Doha, Qatar

Correspondence to Dr Mohamed A Syed;

ahmed.sy3d@gmail.com

Received 14 November 2018 Revised 15 April 2019 Accepted 18 April 2019 Published Online First 17 May 2019



© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Syed MA, Alnuaimi AS, Zainel AJ, *et al. bmjnph* 2019;**2**:20–29.

INTRODUCTION

approach.

(183/1000).

Non-communicable diseases (NCDs) are diseases or conditions which are non-transmittable and chronic in nature. The causes of NCDs are multifactorial; these diseases may arise from any combination of underlying, modifiable and non-modifiable risk factors.¹ Research indicates that socioeconomic, cultural, political and environmental determinants, including population ageing, globalisation, urbanisation and the accompanied nutrition transition, contribute to the increase in NCDs.¹ Four common behavioural risk factors (poor diet, physical inactivity, tobacco use and excessive alcohol consumption) are associated with four disease clusters (cardiovascular diseases (coronary heart disease, stroke and peripheral vascular disease), cancers, chronic obstructive pulmonary diseases (COPD) and type 2 diabetes (T2DM)) that account for about 80% of deaths from NCDs.²

The burden of NCDs is rising rapidly and has now become a major challenge to global development.³ This is despite the fact that NCDs are preventable through feasible and cost-effective public health interventions. Globally, NCDs are responsible for 40 million deaths each year, equivalent to 70% of all deaths. Eighty per cent of all NCD deaths (32 million) are caused by the four disease clusters (cardiovascular diseases, cancers, COPD and diabetes).⁴ Cardiovascular diseases accounts for the highest proportion of NCD deaths annually (17.7 million), followed by cancers (8.8 million), respiratory diseases (3.9 million) and diabetes (1.6 million).⁴

In Qatar, as with other countries, NCDs have been the leading cause of death.⁵ In order to develop NCD-related action plans, policies and interventions, country-specific epidemiological information with regard to NCDs is essential. Studies such as the national STEPwise survey have been conducted and provide valuable information, however, they include Qataris only.⁶ Given expatriates account for 88% of Qatar's population,⁷ studies which also include them are required. This study aims to describe the prevalence of four NCDs clusters by age, gender and nationality (Qatari and non-Qatari) accessing publicly funded primary care services to inform healthcare planning and strategies.

METHODOLOGY Study setting

Qatar, a peninsular Arab country with a backed by the world's third-largest natural gas and oil reserves, has been investing significantly in its healthcare system. This includes a universal publicly funded primary healthcare service delivered by the Primary Healthcare Corporation (PHCC). PHCC is the largest primary care provider in the country publicly with 27 health centres (all accredited by Accreditation Canada International and distributed across three geographical regions).

Study population and data collection

The study population includes both Qataris and non-Qataris registered at a PHCC health centre, aged ≥ 18 and who visited a health centre between 1 January 2017 and 31 December 2017. Demographic and diagnosis data were extracted from the electronic medical records for the defined population.

Data analysis

All data were analysed using the 'Statistical Package for the Social Sciences' statistical software package. Basic descriptive statistics were used to analyse the population characteristics (age, gender and nationality; see online supplementary file for classification) and four NCDs clusters (cardiovascular diseases (coronary heart disease, stroke and peripheral vascular disease), cancers, COPD and T2DM).

Crude prevalence rates for NCDs by age, gender and nationality were calculated. Age-adjusted prevalence rates were also calculated using the WHO World Standard Population (2000–2025) to allow comparisons.⁸

Ethical considerations

The study presented a minimal risk of harm to its subjects, and the data collected for it were anonymised. None of the subjects' personal information was available to the research team. Overall, the study was conducted with integrity according to generally accepted ethical principles and was approved by the PHCC's independent ethics committee (PHCC/RS/18/02/003).

RESULTS

Population characteristics

The study found a total of 421 283 individuals accessed primary healthcare services in 2017 (table 1). Individuals in the 30–39 year age group accounted for approximately 33% of the population. 50.6% of the study population was women. 25.6% of the population was Qatari and 74.4% non-Qatari. The largest non-Qatari nationalities were represented by Southern Asian (30.4%), Northern African (17%) and Western Asian (13.6%). They accounted for 61% of the total study population. Approximately 16% (N=68 421) of the total study population had one or more NCD. The overall age-adjusted prevalence of CHD, stroke, PVD, cancers, COPD and T2DM in the population was 16, 1, 0.3, 6.1, 3 and 201.4 per 1000 population, respectively (table 2). Increasing age-adjusted prevalence rates with increasing age are observed. Higher rates were seen in men compared with women for all NCDs except cancers.

Prevalence of NCDs by nationality

Age-adjusted prevalence rates for CHD, strokes and (CHD=15.07/1000; PVD were similar in Qataris strokes=1.3/1000; PVD=0.27) and non-Oataris (CHD=16.59/1000; strokes=0.91/1000; PVD=0.29) (table 3). Among non-Qataris, CHD was most common in Southern Asians (19.3/1000) and Western Asians (17.3/1000); strokes were most common in Sub-Saharan Africans (1.65/1000) and Western Asians (0.97/1000); and PVD was most common in South-Eastern Asians (0.54/1000) and Western Asians (0.41/1000).

Age-adjusted prevalence rates for cancers were similar between Qataris (6.37/1000) and non-Qataris (6.01/1000) (table 4). Among non-Qataris, cancers were most common in Australian and New Zealanders (15.09/1000) and Northern Europeans (9.88/1000).

Qataris has a slightly higher (3.95/1000) age-adjusted prevalence rate for COPD compared with non-Qataris (2.64/1000) (table 5). Western Europeans (8.01/1000) and Western Asians (3.69/1000) had the highest prevalence among non-Qataris.

T2DM was higher in Qataris (230.4/1000) compared with non-Qataris (188.3/1000) (table 6). Southern Asians (219/1000) and Northern Africans (184/1000) were found to have the highest prevalence among non-Qataris.

DISCUSSION

Globally, the prevalence of risk factors, morbidity and mortality associated with NCDs is on the rise. Prevalence of NCD-related risk factors in the Gulf Cooperation Council (GCC) states has been reported to be among the highest in the world.⁹ Therefore, in Qatar, a member of the GCC, epidemiological information to facilitate healthcare planning and strategies are much needed. This study is potentially the first comprehensive study describing the prevalence of NCDs which includes both Qatari and non-Qatari populations in publicly funded primary care settings. The study found 16.2% of the overall population in publicly funded primary care settings in Qatar had one or more NCD. This highlights the burden of NCDs in the country.

At ageing, many more people are exposed to the risk factors for long periods until the complications develop and they experience the clinical syndromes of NCDs.¹⁰ Similar increasing trends were seen in the prevalence of NCDs with age in this study. Highest increases in the prevalence of NCDs were seen in a relatively young age group

Table 1 F	Table 1 Population characteristics of patients atter	sristics of par	tients attend	nding publicly funded primary health centres in 2017 by age, gender and nationality	funded prima	ary health c	entres in 201	7 by age, ge	nder and na	ationality		
		18-29 years		30–39 years	s	40-49 years		50-59 years		≥60 years		Total
Nationality		Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	%
Qatari (% of total)	f total)	20 569 (32.8%)	16 863 (37.3%)	14 049 (18.4%)	9469 (15.8%)	10 707 (25.0%)	7224 (16.5%)	9084 (36.0%)	5973 (20.6%)	7673 (47.8%)	6096 (30.6%)	107 707 (25.6%
Non-Qatari	Non-Qatari Northern Africa	9753	5404	14 109	12 883	6142	9315	3122	6004	1585	3279	71 596 (17.0
	Sub-Saharan Africa	2185	778	2860	1227	942	757	330	339	154	224	9796 (2.3%
	Latin America and the Caribbean	39	20	96	37	55	35	44	27	16	14	383 (0.1%
	Northern America	308	161	284	157	302	277	250	338	126	221	2424 (0.6%

Methodily Fanel Rande Rande			18-29 years		30–39 years	6	40-49 years	5	50-59 years	(0)	≥60 years		Total
20560 16 853 14 049 9469 10 707 7224 9084 5973 7673 323 8% (37.3%) (18.4%) (15.5%) (15.5%) (36.0%) (17.3%) (17.3%) em Africa 9733 5404 14 109 12.883 6142 9315 3122 6004 1585 773 Saharan Africa 9783 7404 14 109 12.883 6142 757 330 339 154 America 308 161 284 157 942 757 330 338 154 iem America 308 161 284 157 302 277 16 iem America 308 1527 1368 8846 1056 2776 16 iem America 5605 1437 322 2794 17 11 hem America 179 274 5104 5210 3294 165 2764 17 hem Americore 178	Nationality		Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	%
It Northern Mrica 9753 5404 1109 12 883 6142 9315 3122 6004 1585 3272 Sub-Saharan Mrica 2185 778 2860 1227 942 757 330 339 154 222 Latin America and 308 161 284 157 326 339 154 22 Italin America and 308 161 284 157 326 338 154 22 Northern America 308 161 284 157 302 273 16 11 Asia 1177 5605 143 14975 1368 8846 1056 2792 613 487 16 Asia 11177 5605 10226 724 5947 5946 11655 2764 634 Vestern Europe 283 614 272 5846 11955 2764 634 Vestern Europe 283 282 56547	Qatari (% o'	f total)	20 569 (32.8%)	16 863 (37.3%)	14 049 (18.4%)	9469 (15.8%)	10 707 (25.0%)	7224 (16.5%)	9084 (36.0%)	5973 (20.6%)	7673 (47.8%)	6096 (30.6%)	107 707 (25.6%)
Sub-Saharan Africa 2185 778 2860 1227 942 757 330 339 154 221 Latin America and the Cabbean 39 20 96 37 55 35 44 27 16 1 Nurthern America 308 161 284 157 302 176 277 16 17 16 17 Nurthern Asia 1107 5605 443 1296 161 27 291 16 17 South-Eastern Asia 11177 5605 1363 8846 1056 2792 613 16 11 Southern Asia 11177 5605 10226 7224 9978 19047 5846 1183 3332 Southern Asia 11177 5605 1022 724 5136 3342 5246 5346 1060 Western Asia 11177 5602 102 <td>Non-Qatari</td> <td>Northern Africa</td> <td>9753</td> <td>5404</td> <td>14 109</td> <td>12 883</td> <td>6142</td> <td>9315</td> <td>3122</td> <td>6004</td> <td>1585</td> <td>3279</td> <td>71 596 (17.0%)</td>	Non-Qatari	Northern Africa	9753	5404	14 109	12 883	6142	9315	3122	6004	1585	3279	71 596 (17.0%)
Latin America and the Caribbean 39 20 96 37 55 35 44 27 16 11 the Caribbean 308 161 284 157 302 277 250 338 126 22 Northern America 308 161 284 113 27 260 338 126 22 Eastern and Central 129 244 128 8846 1056 2792 613 487 16 11 South-masia 11177 5605 10 226 724 5946 11955 2764 634 South-masia 11177 5605 10 22 5846 11955 2764 634 Western Asia 11177 5605 10 22 303		Sub-Saharan Africa	2185	778	2860	1227	942	757	330	339	154	224	9796 (2.3%)
Northern America 308 161 284 157 302 277 250 338 126 22 Eastern and Central Asia 129 24 128 46 61 27 23 14 11 1 Asia south-Eastern Asia 5605 443 14975 1368 8846 1056 2792 613 487 168 South-Eastern Asia 11177 5605 10226 7224 5047 5976 5133 3073 3333 Western Asia 11177 5605 10226 7224 5047 5210 3294 3183 3073 3333 Western Europe 97 497 5210 3294 3183 3073 3333 Western Europe 97 497 5210 3294 3183 3073 3333 Western Europe 97 497 510 3294 318 407 52 54 12 20 20 20		Latin America and the Caribbean	30	20	96	37	55	35	44	27	16	14	383 (0.1%)
Eastern and Central 129 24 128 66 1 27 23 14 11 11 Asia south-Eastern Asia 1605 443 14975 1368 8846 1056 2792 613 487 166 South-Eastern Asia 11953 15 279 18 295 26 547 9978 19 047 5846 11 955 2764 6343 Western Asia 11 177 5605 10 226 7224 5047 5210 3294 3183 3073 3333 Western Asia 11 177 5605 10 226 7224 5047 5210 3294 3183 3073 3333 Western Europe 135 26 1226 722 54 106 22 116 20 2		Northern America	308	161	284	157	302	277	250	338	126	221	2424 (0.6%)
South-Eastern Asia 5605 443 14 975 1368 8846 1056 2792 613 487 163 Southern Asia 11 963 15 279 18 295 26 547 9978 19 047 5846 11 955 2764 6343 Western Asia 11 177 5605 10 226 7224 5047 5210 3294 3183 3073 3335 Western Asia 111 77 5605 10 226 7224 5047 5210 3294 3183 3073 3335 Western Lurope 135 26 232 54 102 329 318 3073 335 Northern Europe 263 94 102 329 364 116 56 62 118 2 Northern Europe 28 94 102 329 364 106 23 12 12 2 12 2 12 2 12 2 12 2 12 2		Eastern and Central Asia	129	24	128	46	61	27	23	14	1	10	473 (0.11%)
Southern Asia 11 9G3 15 279 18 295 26 547 9978 19 047 5846 11 955 2764 6342 Western Asia 11 177 5605 10 226 7224 5017 5210 3294 3183 3073 3333 Western Asia 11 177 5605 10 226 7224 5017 510 3294 3183 3073 3333 Western Europe 135 26 232 54 102 384 219 219 22 Northern Europe 58 18 170 320 384 206 237 89 110 Northern Europe 58 18 1102 384 206 237 89 110 Southern Europe 58 18 116 116 56 62 18 110 Western Europe 58 18 86 90 43 57 20 20 20 20 20 20 <		South-Eastern Asia	5605	443	14 975	1368	8846	1056	2792	613	487	168	36 353 (8.6%)
Western Asia 11 177 5605 10 226 7224 5047 5210 3294 3183 3073 3333 (excluding Gatar) 1135 26 26 322 54 102 38 317 23 3073 3333 Eastern Europe 135 26 263 34 1102 384 20 18 21 110 22 18 21 111 22 18 111 22 23 24 20 20 20 20 20 20 20 20		Southern Asia	11 963	15 279	18 295	26 547	9978	19 047	5846	11 955	2764	6342	128 016 (30.4%)
Eastern Europe1352623254102383122182Northern Europe974945722032036420623789110Southern Europe9749197991191165662182Western Europe58181204986904357202Western Europe58181204986904357202Australasia3421515152525254123Mostern Europe67.2%(81.6%)(81.6%)(84.2%)(75.0%)(83.5%)(64.0%)(79.4%)(52.2%)(69.3%)Mostern Europe21333102222Mostern Europe5862.7%)(81.6%)(84.2%)(75.0%)(83.5%)(64.0%)(79.4%)(52.2%)(69.3%)Mostern Europe21333102223Mostern Europe62.0%(81.6%)(84.2%)(75.0%)(83.5%)(64.0%)(79.4%)(52.2%)(69.3%)Mostern Europe2131020222Mostern Europe83.0%(64.2%)(75.0%)(83.5%)(64.0%)(79.4%)(52.2%)(69.3%)Mostern Europe221		Western Asia (excluding Qatar)	11 177	5605	10 226	7224	5047	5210	3294	3183	3073	3335	57 164 (13.6%)
Northern Europe 263 94 457 220 320 364 206 237 89 111 Southern Europe 97 49 197 99 119 116 56 62 18 2 Western Europe 58 18 120 49 86 90 43 57 200 2 Western Europe 58 18 120 49 86 90 43 57 20 2 Australasia 34 21 51 31 51 52 52 54 12 3 Australasia 4223 28366 6247 6076 8247 6376 83566 64.06 790 7306 8373 13804 67.266 62.776 81.666 8247 50376 32.92 3654 16183 23026 8373 13804 67.266 62.776 81.666 8247 63.266 62.076 62.266 690 2 2 2 2 2 1 3 1 0 2 0 2 0 2 2 2 2 62.04 45230 76.480 59.846 42.890 43.790 25.07 29.01 16.048 1900		Eastern Europe	135	26	232	54	102	38	31	22	18	20	678 (0.2%)
Southern Europe 97 49 197 99 119 116 56 62 18 2 Western Europe 58 18 120 49 86 90 43 57 20 2 2 Mestern Europe 58 18 120 49 86 90 43 57 20 2 2 2 2 2 3		Northern Europe	263	94	457	220	320	364	206	237	89	110	2360 (0.6%)
Western Europe 58 18 120 49 86 90 43 57 20 2 Australasia 34 21 51 31 51 52 54 12 3 Australasia 34 21 51 51 52 54 12 3 Mustralasia 42 233 28 66 47 50 376 32 192 36 64.0% (70.4%) (70.3%) (83.5%) (64.0%) (79.4%) (52.2%) (69.3%)<		Southern Europe	97	49	197	66	119	116	56	62	18	25	838 (0.2%)
Australasia 34 21 51 31 51 52 52 54 12 3 n 42 233 28 56 62 447 50 376 32 192 36 54 12 38 n 42 233 28 56 62 447 50 376 33 13 804 n 67 (67.2%) (81.6%) (84.2%) (75.0%) (83.5%) (64.0%) (79.4%) (52.2%) (69.3%) 2 1 3 1 0 2 0 2 2 2 2 1 3 1 0 2 0 2 2 2 2 2 1 3 1 0 2 0 2 2 2 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 <		Western Europe	58	18	120	49	86	06	43	57	20	25	566 (0.1%)
ri 42 233 28 366 62 47 50 376 32 192 36 564 16 183 23 026 8373 13 804 (67.2%) (62.7%) (81.6%) (84.2%) (75.0%) (83.5%) (64.0%) (79.4%) (52.2%) (69.3%) 2 1 3 1 0 2 0 2 2 2 1 3 1 0 2 0 2 2 62 804 45 230 76 438 59 846 42 899 43 790 25 267 29 001 16 048 19 900		Australasia	34	21	51	31	51	52	52	54	12	31	389 (0.1%)
2 1 3 1 0 2 2 2 2 62 804 45 230 76 498 59 846 42 899 43 790 25 267 29 001 16 048 19 900	Non-Qatari (% of total)		42 233 (67.2%)	28 366 (62.7%)	62 447 (81.6%)	50 376 (84.2%)	32 192 (75.0%)	36 564 (83.5%)	16 183 (64.0%)	23 026 (79.4%)	8373 (52.2%)	13 804 (69.3 <i>%</i>)	313 564 (74.4%)
62 804 45 230 76 498 59 846 42 899 43 790 25 267 29 001 16 048	Unknown		2	-	ო	-	0	2	0	2	5	0	13 (0.0%)
	Total All		62 804	45 230	76 498	59 846	42 899	43 790	25 267	29 001	16 048	19 900	421 283 (100.0%)

6

NGL Constructions Constructions N Cardiovacourar disease and its complications Crude rate (1000) Mate Thombotic/naemonthagic N Age-adjusted rate (1000) Mate Thombotic/naemonthagic N Crude rate (1000) Mate Thombotic/naemonthagic N Age-adjusted rate (1000) Mate Peripheral vascular disease N Crude rate (1000) Mate Age-adjusted rate (1000) Mate Emate Emate Dators N Age-adjusted rate (1000) Mate Age-adjusted rate (1000) Mate Emate Emate Cators N Age-adjusted rate (1000) Mate Age-adjusted rate (1000) Mate Emate Emate Cators N Age-adjusted rate (1000) Mate Age-adjusted rate (1000) Mate Emate Emate Cators N Crude rate (1000) Mate Age-adjusted rate (1000) Mate Emate Emate Age-adjusted rate (1000) Mate Mate Mate Age-adjuster (1000) Mate <td< th=""><th>18–29 years 12 0.11 0.15 0.08 6 0.06</th><th>30-39 years 0.73 0.73 0.4 15 0.4 0.11</th><th>40-49 years 458 5.28 8.6 1.9 49 0.6</th><th>50–59 years 1144 21.08</th><th>≥60 years</th><th>Total</th><th></th></td<>	18–29 years 12 0.11 0.15 0.08 6 0.06	30-39 years 0.73 0.73 0.4 15 0.4 0.11	40-49 years 458 5.28 8.6 1.9 49 0.6	50–59 years 1144 21.08	≥60 years	Total	
Coronary heart disease and its complications N Thrombotic/haemorrhagic Age-adjusted rate (/1000) Thrombotic/haemorrhagic N Thrombotic/haemorrhagic N Peripheral vascular disease N Peripheral vascular disease N Age-adjusted rate (/1000) Age-adjusted rate (/1000) Age-adjusted rate (/1000) Age-adjusted rate (/1000) Age-adjusted rate (/1000) N Age-adjusted rate (/1000) Age-adjusted rate (/1000) Age-adjusted rate (/1000) N Age-adjusted rate (/1000) N Age-adjusted rate (/1000) N Age-adjusted rate (/1000) N	12 0.11 0.08 6 0.06	100 0.73 1.22 0.4 15 0.11	458 5.28 8.6 49 0.6	1144 21.08		10-10 010C	
Crude rate (/1000) Age-adjusted rate (/1000) Inbotic/haemorrhagic N Crude rate (/1000) Age-adjusted rate (/1000) Age-adjusted rate (/1000) Interl vascular disease N Age-adjusted rate (/1000) Age-adjusted rate (/1000) Age-adjusted rate (/1000) Age-adjusted rate (/1000) N N Age-adjusted rate (/1000)	0.11 0.08 6 0.06	0.73 1.22 0.4 0.11 0.2	5.28 8.6 49 0.6	21.08	2457	Male=3180 Female=986	4171
Age-adjusted rate (1000) abotic/haemorrhagic N Crude rate (1000) Crude rate (1000) aral vascular disease N Age-adjusted rate (1000) Age-adjusted rate (1000) Crude rate (1000) Age-adjusted rate (1000) Age-adjusted rate (1000) Age-adjusted rate (1000) Age-adjusted rate (1000)	0.15 0.08 6 0.06	1.22 0.4 0.11 0.2	8.6 49 0.6		68.3	Male=16.1	9.9
Age-adjusted rate (/1000) botic/haemorrhagic N crude rate (/1000) Age-adjusted rate (/1000) reral vascular disease N Crude rate (/1000) Age-adjusted rate (/1000) Age-adjusted rate (/1000) Age-adjusted rate (/1000) N N N Age-adjusted rate (/1000) N N Age-adjusted rate (/1000) Age-adjusted rate (/1000)	0.15 0.08 6 0.06	1.22 0.4 15 0.11	8.6 1.9 0.6			Female=4.4	
Indotic/haemorrhagic N Indotic/haemorrhagic Crude rate (/1000) Re-adjusted rate (/1000) Age-adjusted rate (/1000) Indotic N Indotic N Indotic Crude rate (/1000) Indotic Age-adjusted rate (/1000) Indotic N Indotic Crude rate (/1000) Indotic Age-adjusted rate (/1000) Indotic N Indotic Age-adjusted rate (/1000)	0.08 6 0.06	0.4 15 0.11	1.9 49 0.6	32.5	89.9	22.2	16
Indotic/haemorrhagic N Crude rate (/1000) Age-adjusted rate (/1000) Interal vascular disease N Age-adjusted rate (/1000) Age-adjusted rate (/1000) Age-adjusted rate (/1000) Age-adjusted rate (/1000) N N Age-adjusted rate (/1000)	6 0.06	15 0.11 0.2	49 0.6	80	41.7	8.86	
Crude rate (/1000) Age-adjusted rate (/1000) heral vascular disease N Age-adjusted rate (/1000) Crude rate (/1000) Crude rate (/1000) Age-adjusted rate (/1000) N N Age-adjusted rate (/1000) N N N Age-adjusted rate (/1000) Age-adjusted rate (/1000)	0.06	0.11	0.6	69	150	Male=203	289
Crude rate (/1000) Age-adjusted rate (/1000) Peral vascular disease N Age-adjusted rate (/1000) N Crude rate (/1000) Age-adjusted rate (/1000) Age-adjusted rate (/1000) N N N N Age-adjusted rate (/1000)	0.06	0.11 0.2	0.6			Female=86	
Age-adjusted rate (/1000) neral vascular disease N Crude rate (/1000) Age-adjusted rate (/1000) N Crude rate (/1000) Age-adjusted rate (/1000)		0.2		1.27	4.2	Male=1	0.69
Age-acjusted rate (/1000) reral vascular disease N Crude rate (/1000) Age-acjusted rate (/1000) N Crude rate (/1000) Age-acjusted rate (/1000) Age-acjusted rate (/1000)		0.2				Female=0.4	
neral vascular disease N Crude rate (/1000) Age-adjusted rate (/1000) N Crude rate (/1000) Age-adjusted rate (/1000)	0.1		0.7	1.9	5.1	1.4	-
neral vascular disease N Crude rate (/1000) Age-adjusted rate (/1000) N Crude rate (/1000) Age-adjusted rate (/1000)	0.1	0.1	0.4	0.6	ო	0.7	
Crude rate (/1000) Age-adjusted rate (/1000) N Crude rate (/1000) Age-adjusted rate (/1000)	4	œ	17	19	38	Male=63	86
Crude rate (/1000) Age-adjusted rate (/1000) N Crude rate (/1000) Age-adjusted rate (/1000)						Female=23	
Age-adjusted rate (/1000) N Crude rate (/1000) Age-adjusted rate (/1000) N	0.1	0.1	0.2	0.4	1.1	Male=0.3	0.2
Age-adjusted rate (/1000) N Crude rate (/1000) Age-adjusted rate (/1000)						Female=0.1	
N Crude rate (/1000) Age-adjusted rate (/1000) N	0.1	0.1	0.3	0.5	1.5	0.4	0.3
N Crude rate (/1000) Age-adjusted rate (/1000) N	0.1	0.1	0.1	0.2	0.5	0.1	
Crude rate (/1000) Age-adjusted rate (/1000) N	290	698	653	448	347	Male=800	2436
Crude rate (/1000) Age-adjusted rate (/1000) N						Female=1636	
Age-adjusted rate (/1000) N	2.7	5.12	7.5	8.26	9.7	Male=4	5.8
Age-adjusted rate (/1000) N						Female=7.3	
z	0	3.26	4	5.07	9.9	4.4	6.1
	3.2	6.58	11.2	11.91	9.4	7.7	
	37	78	145	192	418	Male=691	870
						Female=179	
Crude rate (/1000)	0.3	0.57	1.7	3.5	11.6	Male=3.5	0
						Female=0.8	
Age-adjusted rate (/1000) Male	0.7	-	2.7	5.5	16.2	4.5	က
Female	0.1	0.2	0.7	1.3	9	1.4	

BMJ Nutrition, Prevention & Health

(30-49 years). These findings suggest the early onset of NCDs in the population that needs to be addressed.

Previous research has reported significant differences in health status and NCD prevalence between men and n.¹¹ These can be attributed to the different levels of ure and vulnerability to NCD risk factors. Research gs show women compared with men are more likely ort worse overall health globally.¹⁰ The findings study, however, found higher prevalence rates of (except cancers) in men compared with women. an be attributed to a lower overall life expectancy n in Qatar and their higher probability of dying en the ages of 15 and 60 years of age compared with n.¹² These findings suggest that gender differences ar may be different to other countries and together ght gender inequalities which need to be studied r.

alence rates of CHD and cancers in the study were to be similar in both Qataris and non-Qataris; er, COPD and T2DM rates were higher in Qataris ured with non-Qataris. In terms of non-Qataris by , 7 of the 14 regional populations accounted for a ty of the NCDs-Qataris, North Americans, Austrad New Zealanders, Western Asian, Southern Asian, ern African and Northern Europeans. T2DM nted for the highest prevalence of any NCD among Dataris (230/1000) and non-Qataris (183/1000). findings are similar to those from other countries large number of migrants, for example, there is ce from the UK suggesting differences in NCDs on an individual's country of birth and ethnicity.¹³

abolic syndrome (MS) defined a combination of lual modifiable risk factors (abdominal obesity, blood pressure, raised fasting blood glucose, raised erides and reduced high-density lipoprotein cholesthat are associated with NCDs.⁶ In a previous study Qatar, the prevalence of MS was found to be 28% g Qataris. The study also reported the prevalence of significantly increase with age and higher in Qatari ompared with women.⁶ These findings are in line ne findings of this study as the prevalence of NCD butable to the prevalence of MS. They suggest a for a focused approach to addressing modifiable ctors to reduce NCD prevalence in Qatar.

re are evidence that show NCD-related healthnterventions are cost-effective if provided early ured with costly procedures at advanced stages of es.¹⁴ Based on the observations of this study, any tive strategies will require identifying socio-dephic and environmental correlates (particularly influencing men and specific nationalities) and ssing risk factors. Primary care is for most patients teway to the healthcare system, yet in resource-limettings, most primary healthcare is focused on episodic care and chronic disease is often deferred ecialist care delivered at secondary and tertiary s.¹⁵ The findings of the study call for improvement reater investment in the prevention and control

		women
		exposu finding
		to repo
188.1		of this
μ		NCDs
		This ca
		in mer
576.2		betwee
ŝ		women in Qata
		highlig
4		further
352.4		Preva
		found
		howeve
133.6		compa
-		region,
		majorit
сi		lian an Northe
39.2		accoun
		both Q
		These
15		with a
		eviden
		based o
		Meta
Θ		individ raised l
Female		triglyce
ŭ		terol) t
		from Q
		among
		MS to s
		men co
		with th
		is attril need f
		risk fac
		Ther
		care ir
		compa
		disease
		preven
	ase.	mograj
	dise	those i address
	able	the gat
	CD, non-communicable disease.	ited se
	comr	acute e
	- uo u	to spe
	(CD,	centres
	2	and gr
		S

64 818

153.9

Female=27 814 Male=187

Male=37 004

20 571

20 728

14 842

6996

1681

Total

≥60 years

50-59 years

40-49 years

30–39 years

18-29 years

201.4

Female=124 214.9

569

407.68

208

16.6

Age-adjusted rate (/1000) Male

c 66.8

572

382

171.2

51.3

5.6

Crude rate (/1000)

z

Type 2 diabetes mellitus

NCD

Continued

Table 2

NCD		Nationality		18–29 years	30–39 years	40-49 years	50-59 years	≥60 years	z	Crude rate (/1000)	Age-adjusted rate (/1000) *
Cardiovascular disease	Coronary heart disease	Qatari		0.16	0.68	4.96	18.33	65.15	1284	11.92	15.07
	and its complications	Non-Qatari	Northern Africa	0.2	.	5.37	22.57	55.72	590	8.24	14.19
			Sub-Saharan Africa	0	0.24	2.35	5.98	44.97	26	2.65	9.16
			Latin America and the Caribbean	0	0	0	0	(66.67)	2	5.22	(11.59)
			Northern America	0	0	6.91	18.71	69.16	39	16.09	15.99
			Eastern and Central Asia	0	0	11.36	(0)	(47.62)	0	4.23	(10.37)
			South-Eastern Asia	0	0.24	2.22	4.41	24.43	57	1.57	5.35
			Southern Asia	0.04	0.94	6.61	26.63	81.05	1447	11.3	19.35
			Western Asia (excluding Qatar)	0.11	0.55	5.77	22.56	74.28	200	11.73	17.37
			Eastern Europe	0	0	0	0	(105.26)	4	5.9	(18.29)
			Northern Europe	0	0	1.46	6.77	15.08	7	2.97	3.87
			Southern Europe	0	0	0	8.47	(46.51)	ო	3.58	(6.3)
			Western Europe	0	0	5.68	0	(88.89)	5	8.83	(16.49)
			Australasia	0	0	0	28.3	(46.51)	5	12.85	(12.16)
		Non-Qatari (total)	otal)	0.08	0.74	5.37	22.14	70.34	2887	9.21	16.59
	Thrombotic/haemorrhagic	Qatari		0.05	0.13	0.73	1.26	5.45	112	1.04	1.3
	stroke	Non-Qatari	Northern Africa	0	0.11	0.71	0.99	3.08	38	0.53	0.83
			Sub-Saharan Africa	0	0.24	1.18	0	7.94	9	0.61	1.65
			Latin America and the Caribbean	0	0	0	0	(0)	0	0	(0)
			Northern America	0	0	0	0	0	0	0	0
			Eastern and Central Asia	0	0	0	(0)	(0)	0	0	(0)
			South-Eastern Asia	0	0	0.61	0.29	1.53	Ø	0.22	0.42
			Southern Asia	0.11	0.16	0.41	1.74	3.4	84	0.66	0.98
			Western Asia (excluding Qatar)	0.06	0.05	0.47	1.2	3.9	40	0.67	0.97
			Eastern Europe	0	0	0	0	(0)	0	0	(0)
			Northern Europe	0	0	0	2.26	0		0.42	0.33
			Southern Europe	0	0	0	0	(0)	0	0	(0)
			Western Europe	0	0	0	0	(0)	0	0	(0)
			Australasia	0	0	0	0	(0)	0	0	(0)
		Non-Qatari (total)	otal)	0.06	0.11	0.52	1.28	3.38	177	0.56	0.91

9

25

Table 3 Continued											
NCD		Nationality		18–29 years	30–39 years	40-49 years	50-59 years	≥60 years	z	Crude rate (/1000)	Age-adjusted rate (/1000) *
	Peripheral vascular	Qatari		0.05	0.04	0.11	0.27	1.09	24	0.22	0.27
	disease	Non-Qatari	Northern Africa	0.07	0.19	0.39	0.66	0.21	19	0.27	0.27
			Sub-Saharan Africa	0	0	0	0	0	0	0	0
			Latin America and the Caribbean	0	0	0	0	(0)	0	0	(0)
			Northern America	0	0	0	1.7	0	.	0.41	0.25
			Eastern and Central Asia	0	0	0	(0)	(0)	0	0	(0)
			South-Eastern Asia	0	0.06	0	0	3.05	ი	0.08	0.54
			Southern Asia	0	0	0.24	0.39	0.88	22	0.17	0.25
			Western Asia (excluding Qatar)	0.06	0.05	0.19	0.15	1.87	17	0.28	0.41
			Eastern Europe	0	0	0	0	(0)	0	0	(0)
			Northern Europe	0	0	0	0	0	0	0	0
			Southern Europe	0	0	0	0	(0)	0	0	(0)
			Western Europe	0	0	0	0	(0)	0	0	(0)
			Australasia	0	0	0	0	(0)	0	0	(0)
		Non-Qatari (total)	tal)	0.03	0.06	0.22	0.38	1.04	62	0.2	0.29
	••••										

*Figures (rates) enclosed within parentheses were based (or one of its components) on <50 unweighted observations.

Table 4 Prevalence of cancer by nationality in publicly funded primary health settings

										Age- adjusted
NCD	Nationality		18–29 years	30–39 years	40–49 years	50–59 years	≥60 years	N	Crude rate (/1000)	rate (/1000)
Cancer	Qatari		2.19	4.34	8.53	10.76	9.8	634	5.89	6.37
	Non-Qatari	Northern Africa	3.17	6.78	9.7	8.88	9.66	509	7.11	7.09
		Sub-Saharan Africa	3.37	9.05	11.77	7.47	18.52	79	8.06	9.36
		Latin America and the Caribbean	0	15.04	11.11	0	(0)	3	7.83	(5.27)
		Northern America	2.13	9.07	13.82	18.71	11.53	28	11.55	9.79
		Eastern and Central Asia	6.54	0	0	(0)	(0)	1	2.11	(1.86)
		South-Eastern Asia	3.31	5.02	7.37	7.05	7.63	204	5.61	5.72
		Southern Asia	2.83	3.5	4.93	5.17	7.03	533	4.16	4.43
		Western Asia (excluding Qatar)	2.77	6.39	8.51	9.56	12.33	399	6.68	7.24
		Eastern Europe	0	10.49	7.14	18.87	(0)	5	7.37	(6.28)
		Northern Europe	5.6	10.34	11.7	9.03	15.08	24	10.17	9.88
		Southern Europe	0	3.38	17.02	25.42	(0)	8	9.55	(7.52)
		Western Europe	0	5.92	5.68	10	(22.22)	4	7.07	(7.61)
		Australasia	0	24.39	9.71	0	(46.51)	5	12.85	(15.09)
	Non-Qatari (t	otal)	2.95	5.28	7.27	7.29	9.56	1802	5.75	6.01

Figures (rates) enclosed within parentheses were based (or one of its components) on <50 unweighted observations.

*Geographic regions as defined by the United Nations (see https://unstats.un.org/unsd/methodology/m49/).

Table 5 Prevalence of chronic obstructive airway disease by nationality in publicly funded primary health settings

NCD	Nationality		18–29 vears	30–39 vears	40–49 years	50–59 vears	≥60 years	N	Crude rate (/1000)	Age- adjusted rate (/1000) *
Chronic	Qatari		0.59	0.77	3.07	4.25	14.09	353	3.28	3.96
obstructive airway	Non-Qatari	Northern Africa	0.26	0.67	1.75	2.85	9.25	120	1.68	2.55
disease		Sub-Saharan Africa	0	0.24	0.59	0	13.23	7	0.71	2.46
		Latin America and the Caribbean	0	0	0	0	(0)	0	0	(0)
		Northern America	0	0	3.45	0	17.29	8	3.3	3.64
		Eastern and Central Asia	0	0	0	(0)	(0)	0	0	(0)
		South-Eastern Asia	0.17	0.37	0.1	0.88	3.05	13	0.36	0.81
		Southern Asia	0.15	0.49	1.14	3.76	8.13	200	1.56	2.31
		Western Asia (excluding Qatar)	0.34	0.6	2.27	4.48	13.73	159	2.66	3.69
		Eastern Europe	0	3.5	0	0	(0)	1	1.47	(0.75)
		Northern Europe	0	0	2.92	0	10.05	4	1.69	2.29
		Southern Europe	0	0	0	0	(23.26)	1	1.19	(4.04)
		Western Europe	0	5.92	0	20	(22.22)	4	7.07	(8.01)
		Australasia	0	0	0	0	(0)	0	0	(0)
	Non-Qatari	(total)	0.21	0.53	1.31	3.26	10.1	517	1.65	2.64

*Figures (rates) enclosed within parentheses were based (or one of its components) on <50 unweighted observations.

A a a

Ago-

Table 6 Prevalence of type 2 diabetes mellitus by nationality in publicly funded primary health settings

										Age- adjusted
NCD	Nationality	y	18–29 years	30–39 years	40–49 years	50–59 years	≥60 years	N	Crude rate (/1000)	rate (/1000) *
Type 2	Qatari		22.52	68.03	198.2	424.92	642.97	21 248	197.28	230.4
diabetes mellitus	Non-	Northern Africa	14.18	53.72	170.67	359.96	495.68	9999	139.66	184.95
menitus	Qatari	Sub-Saharan Africa	7.76	27.89	123.01	252.62	388.89	662	67.58	134.78
		Latin America and the Caribbean	0	15.04	55.56	112.68	(200)	21	54.83	(64.44)
		Northern America	8.53	13.61	72.54	207.48	340.06	292	120.46	107.68
		Eastern and Central Asia	0	17.24	34.09	(108.11)	(95.24)	12	25.37	(42.1)
		South-Eastern Asia	5.95	17.44	68.98	208.52	354.2	1946	53.53	109.72
		Southern Asia	10.76	61.75	211.02	434.19	587.2	22 263	173.91	219.72
		Western Asia (excluding Qatar)	14.62	40.82	144.17	329.8	526.69	8113	135.92	178.48
		Eastern Europe	0	0	28.57	132.08	(210.53)	19	28.02	(60.89)
		Northern Europe	16.81	20.68	54.09	124.15	216.08	155	65.68	74.59
		Southern Europe	6.85	3.38	12.77	93.22	(46.51)	18	21.48	(26.54)
		Western Europe	13.16	17.75	62.5	90	(222.22)	34	60.07	(70.63)
		Australasia	0	24.39	29.13	132.08	(395.35)	36	92.54	(98.34)
	Non-Qata	ri (Total)	11.87	47.83	164.17	365.48	528.39	43 570	138.95	188.3

*Figures (rates) enclosed within parentheses were based (or one of its components) on <50 unweighted observations.

of NCDs, in particular T2DM, by primary health institutions in Qatar. It must also be noted that appropriately qualified and trained public health professionals to have the appropriate expertise and skills to take the responsibility of planning and providing preventive interventions for NCD patients. Therefore, more investment in such professionals to manage the NCD epidemic in Qatar's primary healthcare system is necessary.

The study has a number of strengths and limitations. Strengths include an up-to-date prevalence of NCDs in primary care in Qatar. This provides a baseline for future longitudinal studies to monitor NCDs and risk factors as well as in health planning and future strategies. The limitations are as follows: First, this was a cross-sectional study and provides a snapshot of the burden at a particular moment in time. Second, the study included only patients who were ≥ 18 years and those who attended a PHCC health centres in 2017; therefore, it is not comprehensive and nationally representative.

CONCLUSIONS

Although not comprehensive and nationally representative, this study is suggestive of a higher prevalence of NCDs among a younger population, men and in Qatari, Western Asian, Southern Asian, Sub-Saharan Africans, South-Eastern Asians Northern African and Western European nationalities. Prevention, treatment and control of NCDs and their risk factors is a public health problem in Qatar, and resources need to be invested towards targeted interventions with a multisectoral approach. **Contributors** MAS designed the study. ASAN, AJALZ and HAQ contributed to the design. ASAN undertook data extraction and analysis. MAS prepared the first draft of the manuscript. ASAN, AJALZ and HAQ contributed to it and approved the final manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval The study was conducted with integrity according to generally accepted ethical principles and was approved by the PHCC's independent ethics committee (PHCC/RS/18/02/003).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD

Mohamed A Syed http://orcid.org/0000-0002-2396-3534

REFERENCES

- Manning K, Senekal M, Harbron J. Non-communicable disease risk factors and treatment preference of obese patients in Cape Town. *Afr J Prim Health Care Fam Med* 2016;8.
- 2. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of Disease Study 2010. *The Lancet* 2012;380:2095–128.
- 3. Habib SH, Saha S. Burden of non-communicable disease: global overview. *Diabetes Metab Syndr* 2010;4:41–7.

BMJ Nutrition, Prevention & Health

- World Health Organisation. Global status report on noncommunicable diseases, 2014. Available: http://www.who.int/nmh/ publications/ncd-status-report-2014/en/ [Accessed on 11th Jan 2018].
- Al-Kaabi SK, Atherton A. Impact of noncommunicable diseases in the state of Qatar. CEOR: Clinico Economics and Outcomes Research, 2015: 7. 377–85.
- 6. Al-Thani MH, Al-Thani AAM, Cheema S, *et al*. Prevalence and determinants of metabolic syndrome in Qatar: results from a national Health survey. *BMJ Open* 2016;6:e009514.
- Priya Dsouza Communications. Population of Qatar by nationality - 2017 report, 2017. Available: http://priyadsouza.com/population-ofqatar-by-nationality-in-2017/ [Accessed on 1th October 2018].
- 8. Ahmad O, Boschi-Pinto C, Lopez AD, et al. Age standardization of rates: a new who standard. Geneva: World Health Organization, 2001.
- Khoja T, Rawaf S, Qidwai W, et al. Health care in Gulf Cooperation Council countries: a review of challenges and opportunities. *Cureus* 2017;9:e1586.

- Abebe SM, Andargie G, Shimeka A, et al. The prevalence of non-communicable diseases in Northwest Ethiopia: survey of Dabat health and demographic surveillance system. BMJ Open 2017;7:e015496.
- Liu Y, Liu G, Wu H, et al. Sex differences in non-communicable disease prevalence in China: a cross-sectional analysis of the China health and retirement longitudinal study in 2011. BMJ Open 2017;7:e017450.
- 12. World Health Organisation. Qatar, 2016. Available: http://www.who. int/countries/qat/en/ [Accessed on 1th Oct 2018].
- Jayaweera H. Migrations and non-communicable diseases, 2013. Available: https://www.compas.ox.ac.uk/2013/migration-and-noncommunicable-diseases/ [Accessed on 28th Mar 2019].
- Endriyas M, Mekonnen E, Dana T, et al. Burden of NCDS in SNNP region, Ethiopia: a retrospective study. BMC Health Serv Res 2018;18.
- Kane J, Landes M, Carroll C, et al. A systematic review of primary care models for non-communicable disease interventions in sub-Saharan Africa. BMC Family Practice 2017;18.